{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:48:28Z","timestamp":1790999308525,"version":"4.1.0"},"reference-count":322,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41582-019-0138-8","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T14:05:28Z","timestamp":1550585128000},"page":"161-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":180,"title":["Therapeutic landscape for Batten disease: current treatments and future prospects"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-942X","authenticated-orcid":false,"given":"Tyler B.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0230-9979","authenticated-orcid":false,"given":"Jacob T.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denia","family":"Ramirez-Montealegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0707-063X","authenticated-orcid":false,"given":"David A.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"key":"138_CR1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1542\/peds.44.4.570","volume":"44","author":"W Zeman","year":"1969","unstructured":"Zeman, W. & Dyken, P. Neuronal ceroid-lipofuscinosis (Batten\u2019s disease): relationship to amaurotic family idiocy? Pediatrics 44, 570\u2013583 (1969).","journal-title":"Pediatrics"},{"key":"138_CR2","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.ajpath.2011.08.036","volume":"179","author":"A Aldrich","year":"2011","unstructured":"Aldrich, A. & Kielian, T. Central nervous system fibrosis is associated with fibrocyte-like infiltrates. Am. J. Pathol. 179, 2952\u20132962 (2011).","journal-title":"Am. J. Pathol."},{"key":"138_CR3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ajmg.1320310606","volume":"5","author":"JA Rider","year":"1988","unstructured":"Rider, J. A. & Rider, D. L. Batten disease: past, present, and future. Am. J. Med. Genet. Suppl. 5, 21\u201326 (1988).","journal-title":"Am. J. Med. Genet. Suppl."},{"key":"138_CR4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0387-7604(88)80075-5","volume":"10","author":"P Santavuori","year":"1988","unstructured":"Santavuori, P. Neuronal ceroid-lipofuscinoses in childhood. Brain Dev. 10, 80\u201383 (1988).","journal-title":"Brain Dev."},{"key":"138_CR5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbamcr.2008.11.004","volume":"1793","author":"A Jalanko","year":"2009","unstructured":"Jalanko, A. & Braulke, T. Neuronal ceroid lipofuscinoses. Biochim. Biophys. Acta 1793, 697\u2013709 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"138_CR6","first-page":"347","volume":"1","author":"OC Stengel","year":"1826","unstructured":"Stengel, O. C. Beretning om et maerkeligt Sygdomstilfaelde hos fire S\u00f8dskende I N\u00e6rheden af R\u00f6raas. Eyr 1, 347\u2013352 (1826).","journal-title":"Eyr"},{"key":"138_CR7","first-page":"386","volume":"23","author":"FE Batten","year":"1903","unstructured":"Batten, F. E. Cerebral degeneration with symmetrical changes in the maculae in two members of a family. Trans. Ophthalmol. Soc. UK 23, 386\u2013390 (1903).","journal-title":"Trans. Ophthalmol. Soc. UK"},{"key":"138_CR8","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1177\/0883073813494813","volume":"28","author":"HR Adams","year":"2013","unstructured":"Adams, H. R. & Mink, J. W., University of Rochester Batten Center Study Group. Neurobehavioral features and natural history of juvenile neuronal ceroid lipofuscinosis (Batten disease). J. Child Neurol. 28, 1128\u20131136 (2013).","journal-title":"J. Child Neurol."},{"key":"138_CR9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.bbadis.2006.06.010","volume":"1762","author":"M Haltia","year":"2006","unstructured":"Haltia, M. The neuronal ceroid-lipofuscinoses: from past to present. Biochim. Biophys. Acta 1762, 850\u2013856 (2006).","journal-title":"Biochim. Biophys. Acta"},{"key":"138_CR10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00316269","volume":"213","author":"HH Goebel","year":"1976","unstructured":"Goebel, H. H., Zeman, W. & Pilz, H. Ultrastructural investigations of peripheral nerves in neuronal ceroid-lipofuscinoses (NCL). J. Neurol. 213, 295\u2013303 (1976).","journal-title":"J. Neurol."},{"key":"138_CR11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00697751","volume":"26","author":"M Haltia","year":"1973","unstructured":"Haltia, M., Rapola, J. & Santavuori, P. Infantile type of so-called neuronal ceroid-lipofuscinosis. Histological and electron microscopic studies. Acta Neuropathol. 26, 157\u2013170 (1973).","journal-title":"Acta Neuropathol."},{"key":"138_CR12","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.bbadis.2012.11.014","volume":"1832","author":"GW Anderson","year":"2013","unstructured":"Anderson, G. W., Goebel, H. H. & Simonati, A. Human pathology in NCL. Biochim. Biophys. Acta 1832, 1807\u20131826 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"138_CR13","first-page":"210","volume":"4","author":"HH Goebel","year":"1985","unstructured":"Goebel, H. H. Fingerprint inclusions in non-vacuolated lymphocytes in juvenile neuronal ceroid-lipofuscinosis. Clin. Neuropathol. 4, 210\u2013213 (1985).","journal-title":"Clin. Neuropathol."},{"key":"138_CR14","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1750-3639.2003.tb00486.x","volume":"13","author":"PC Nijssen","year":"2003","unstructured":"Nijssen, P. C. et al. Autosomal dominant adult neuronal ceroid lipofuscinosis: a novel form of NCL with granular osmiophilic deposits without palmitoyl protein thioesterase 1 deficiency. Brain Pathol. 13, 574\u2013581 (2003).","journal-title":"Brain Pathol."},{"key":"138_CR15","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/brain\/awl107","volume":"129","author":"E Siintola","year":"2006","unstructured":"Siintola, E. et al. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain 129, 1438\u20131445 (2006).","journal-title":"Brain"},{"key":"138_CR16","first-page":"226","volume":"3","author":"U Sandbank","year":"1968","unstructured":"Sandbank, U. Congenital amaurotic idiocy. Pathol. Eur. 3, 226\u2013229 (1968).","journal-title":"Pathol. Eur."},{"key":"138_CR17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2990.1985.tb00041.x","volume":"11","author":"S Humphreys","year":"1985","unstructured":"Humphreys, S., Lake, B. D. & Scholtz, C. L. Congenital amaurotic idiocy \u2014 a pathological, histochemical, biochemical and ultrastructural study. Neuropathol. Appl. Neurobiol. 11, 475\u2013484 (1985).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"138_CR18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0887-8994(92)90054-3","volume":"8","author":"RJ Barohn","year":"1992","unstructured":"Barohn, R. J., Dowd, D. C. & Kagan-Hallet, K. S. Congenital ceroid-lipofuscinosis. Pediatr. Neurol. 8, 54\u201359 (1992).","journal-title":"Pediatr. Neurol."},{"key":"138_CR19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10354-015-0359-4","volume":"165","author":"S Meyer","year":"2015","unstructured":"Meyer, S. et al. Congenital CLN disease in two siblings. Wien. Med. Wochenschr. 165, 210\u2013213 (2015).","journal-title":"Wien. Med. Wochenschr."},{"key":"138_CR20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/jnnp.4.3-4.175","volume":"4","author":"RM Norman","year":"1941","unstructured":"Norman, R. M. & Wood, N. A congenital form of amaurotic family idiocy. J. Neurol. Psychiatry 4, 175\u2013190 (1941).","journal-title":"J. Neurol. Psychiatry"},{"key":"138_CR21","first-page":"119","volume":"95","author":"I Garborg","year":"1987","unstructured":"Garborg, I., Torvik, A., Hals, J., Tangsrud, S. E. & Lindemann, R. Congenital neuronal ceroid lipofuscinosis. A case report. Acta Pathol. Microbiol. Immunol. Scand. A 95, 119\u2013125 (1987).","journal-title":"Acta Pathol. Microbiol. Immunol. Scand. A"},{"key":"138_CR22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/adc.29.143.48","volume":"29","author":"NJ Brown","year":"1954","unstructured":"Brown, N. J., Corner, B. D. & Dodgson, M. C. A second case in the same family of congenital familial cerebral lipoidosis resembling amaurotic family idiocy. Arch. Dis. Child 29, 48\u201354 (1954).","journal-title":"Arch. Dis. Child"},{"key":"138_CR23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00401-008-0426-7","volume":"117","author":"K Fritchie","year":"2009","unstructured":"Fritchie, K. et al. Novel mutation and the first prenatal screening of cathepsin D deficiency (CLN10). Acta Neuropathol. 117, 201\u2013208 (2009).","journal-title":"Acta Neuropathol."},{"key":"138_CR24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0387-7604(95)00012-Z","volume":"17","author":"HH Goebel","year":"1995","unstructured":"Goebel, H. H. et al. Prenatal diagnosis of infantile neuronal ceroid-lipofuscinosis: a combined electron microscopic and molecular genetic approach. Brain Dev. 17, 83\u201388 (1995).","journal-title":"Brain Dev."},{"key":"138_CR25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0092-8674(95)90274-0","volume":"82","author":"TJ Lerner","year":"1995","unstructured":"Lerner, T. J. et al. Isolation of a novel gene underlying Batten disease, CLN3. Cell 82, 949\u2013957 (1995).","journal-title":"Cell"},{"key":"138_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1385\/NMM:1:2:111","volume":"1","author":"JM Weimer","year":"2002","unstructured":"Weimer, J. M., Kriscenski-Perry, E., Elshatory, Y. & Pearce, D. A. The neuronal ceroid lipofuscinoses: mutations in different proteins result in similar disease. Neuromolecular Med. 1, 111\u2013124 (2002).","journal-title":"Neuromolecular Med."},{"key":"138_CR27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","volume":"79","author":"RE Williams","year":"2012","unstructured":"Williams, R. E. & Mole, S. E. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology 79, 183\u2013191 (2012).","journal-title":"Neurology"},{"key":"138_CR28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1399-0004.2009.01214.x","volume":"76","author":"R Kohan","year":"2009","unstructured":"Kohan, R. et al. An integrated strategy for the diagnosis of neuronal ceroid lipofuscinosis types 1 (CLN1) and 2 (CLN2) in eleven Latin American patients. Clin. Genet. 76, 372\u2013382 (2009).","journal-title":"Clin. Genet."},{"key":"138_CR29","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bbadis.2015.05.003","volume":"1852","author":"R Kohan","year":"2015","unstructured":"Kohan, R. et al. The neuronal ceroid lipofuscinoses program: a translational research experience in Argentina. Biochim. Biophys. Acta 1852, 2301\u20132311 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"138_CR30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ajmg.10660","volume":"112","author":"R Steinfeld","year":"2002","unstructured":"Steinfeld, R. et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am. J. Med. Genet. 112, 347\u2013354 (2002).","journal-title":"Am. J. Med. Genet."},{"key":"138_CR31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cct.2013.04.004","volume":"35","author":"EA Blieck de","year":"2013","unstructured":"de Blieck, E. A. et al. Methodology of clinical research in rare diseases: development of a research program\u00a0in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates. Contemp. Clin. Trials 35, 48\u201354 (2013).","journal-title":"Contemp. Clin. Trials"},{"key":"138_CR32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/0883073813494268","volume":"28","author":"JW Mink","year":"2013","unstructured":"Mink, J. W., Augustine, E. F., Adams, H. R., Marshall, F. J. & Kwon, J. M. Classification and natural history of the neuronal ceroid lipofuscinoses. J. Child Neurol. 28, 1101\u20131105 (2013).","journal-title":"J. Child Neurol."},{"key":"138_CR33","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","volume":"2","author":"M Nickel","year":"2018","unstructured":"Nickel, M. et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc. Health 2, 582\u2013590 (2018).","journal-title":"Lancet Child Adolesc. Health"},{"key":"138_CR34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/dmcn.13473","volume":"59","author":"A Simonati","year":"2017","unstructured":"Simonati, A. et al. Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5. Dev. Med. Child Neurol. 59, 815\u2013821 (2017).","journal-title":"Dev. Med. Child Neurol."},{"key":"138_CR35","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/0883073813493665","volume":"28","author":"SB Dolisca","year":"2013","unstructured":"Dolisca, S. B., Mehta, M., Pearce, D. A., Mink, J. W. & Maria, B. L. Batten disease: clinical aspects, molecular mechanisms, translational science, and future directions. J. Child Neurol. 28, 1074\u20131100 (2013).","journal-title":"J. Child Neurol."},{"key":"138_CR36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1750-3639.2004.tb00499.x","volume":"14","author":"HH Goebel","year":"2004","unstructured":"Goebel, H. H. & Wisniewski, K. E. Current state of clinical and morphological features in human NCL. Brain Pathol. 14, 61\u201369 (2004).","journal-title":"Brain Pathol."},{"key":"138_CR37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbadis.2006.07.001","volume":"1762","author":"RE Williams","year":"2006","unstructured":"Williams, R. E. et al. Diagnosis of the neuronal ceroid lipofuscinoses: an update. Biochim. Biophys. Acta 1762, 865\u2013872 (2006).","journal-title":"Biochim. Biophys. Acta"},{"key":"138_CR38","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.bbadis.2015.05.007","volume":"1852","author":"J Radke","year":"2015","unstructured":"Radke, J., Stenzel, W. & Goebel, H. H. Human NCL neuropathology. Biochim. Biophys. Acta 1852, 2262\u20132266 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"138_CR39","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/376584a0","volume":"376","author":"J Vesa","year":"1995","unstructured":"Vesa, J. et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 376, 584\u2013587 (1995).","journal-title":"Nature"},{"key":"138_CR40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1083\/jcb.200610151","volume":"176","author":"J Greaves","year":"2007","unstructured":"Greaves, J. & Chamberlain, L. H. Palmitoylation-dependent protein sorting. J. Cell Biol. 176, 249\u2013254 (2007).","journal-title":"J. Cell Biol."},{"key":"138_CR41","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1046\/j.1471-4159.2003.01602.x","volume":"84","author":"R Kakela","year":"2003","unstructured":"Kakela, R., Somerharju, P. & Tyynela, J. Analysis of phospholipid molecular species in brains from patients with infantile and juvenile neuronal-ceroid lipofuscinosis using liquid chromatography-electrospray ionization mass spectrometry. J. Neurochem. 84, 1051\u20131065 (2003).","journal-title":"J. Neurochem."},{"key":"138_CR42","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/hmg\/ddn028","volume":"17","author":"A Lyly","year":"2008","unstructured":"Lyly, A. et al. Deficiency of the INCL protein Ppt1 results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism. Hum. Mol. Genet. 17, 1406\u20131417 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"138_CR43","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.yexcr.2006.01.034","volume":"312","author":"L Ahtiainen","year":"2006","unstructured":"Ahtiainen, L. et al. Palmitoyl protein thioesterase 1 (PPT1) deficiency causes endocytic defects connected to abnormal saposin processing. Exp. Cell Res. 312, 1540\u20131553 (2006).","journal-title":"Exp. Cell Res."},{"key":"138_CR44","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1093\/hmg\/ddp355","volume":"18","author":"C Kielar","year":"2009","unstructured":"Kielar, C. et al. Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease. Hum. Mol. Genet. 18, 4066\u20134080 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"138_CR45","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1172\/JCI33482","volume":"118","author":"SJ Kim","year":"2008","unstructured":"Kim, S. J. et al. Palmitoyl protein thioesterase-1 deficiency impairs synaptic vesicle recycling at nerve terminals, contributing to neuropathology in humans and mice. J. Clin. Invest. 118, 3075\u20133086 (2008).","journal-title":"J. Clin. Invest."},{"key":"138_CR46","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1172\/JCI3112","volume":"102","author":"AK Das","year":"1998","unstructured":"Das, A. K. et al. Molecular genetics of palmitoyl-protein thioesterase deficiency in the US. J. Clin. Invest. 102, 361\u2013370 (1998).","journal-title":"J. Clin. Invest."},{"key":"138_CR47","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/hmg\/10.13.1431","volume":"10","author":"AK Das","year":"2001","unstructured":"Das, A. K., Lu, J. Y. & Hofmann, S. L. Biochemical analysis of mutations in palmitoyl-protein thioesterase causing infantile and late-onset forms of neuronal ceroid lipofuscinosis. Hum. Mol. Genet. 10, 1431\u20131439 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"138_CR48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.gene.2012.12.058","volume":"516","author":"R Kohan","year":"2013","unstructured":"Kohan, R. et al. Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America. Gene 516, 114\u2013121 (2013).","journal-title":"Gene"},{"key":"138_CR49","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.neuint.2009.07.012","volume":"55","author":"GW Kay","year":"2009","unstructured":"Kay, G. W., Verbeek, M. M., Furlong, J. M., Willemsen, M. A. A. P. & Palmer, D. N. Neuropeptide changes and neuroactive amino acids in CSF from humans and sheep with neuronal ceroid lipofuscinoses (NCLs, Batten disease). Neurochem. Int. 55, 783\u2013788 (2009).","journal-title":"Neurochem. Int."},{"key":"138_CR50","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/jmg.2004.019232","volume":"41","author":"GJ Breedveld","year":"2004","unstructured":"Breedveld, G. J. et al. A new locus for a childhood onset, slowly progressive autosomal recessive spinocerebellar ataxia maps to chromosome 11p15. J. Med. Genet. 41, 858\u2013866 (2004).","journal-title":"J. Med. Genet."},{"key":"138_CR51","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/humu.22292","volume":"34","author":"Y Sun","year":"2013","unstructured":"Sun, Y. et al. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease). Hum. Mutat. 34, 706\u2013713 (2013).","journal-title":"Hum. Mutat."},{"key":"138_CR52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10048-005-0218-3","volume":"6","author":"SE Mole","year":"2005","unstructured":"Mole, S. E., Williams, R. E. & Goebel, H. H. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 6, 107\u2013126 (2005).","journal-title":"Neurogenetics"},{"key":"138_CR53","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamaophthalmol.2017.1401","volume":"135","author":"CA Ku","year":"2017","unstructured":"Ku, C. A. et al. Detailed clinical phenotype and molecular genetic findings in CLN3-associated isolated retinal degeneration. JAMA Ophthalmol. 135, 749\u2013760 (2017).","journal-title":"JAMA Ophthalmol."},{"key":"138_CR54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-2008-1059612","volume":"13","author":"P Santavuori","year":"1982","unstructured":"Santavuori, P., Rapola, J., Sainio, K. & Raitta, C. A variant of Jansky-Bielschowsky disease. Neuropediatrics 13, 135\u2013141 (1982).","journal-title":"Neuropediatrics"},{"key":"138_CR55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-2008-1071423","volume":"22","author":"P Santavuori","year":"1991","unstructured":"Santavuori, P. et al. The spectrum of Jansky-Bielschowsky disease. Neuropediatrics 22, 92\u201396 (1991).","journal-title":"Neuropediatrics"},{"key":"138_CR56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1212\/WNL.0b013e3181cff70d","volume":"74","author":"W Xin","year":"2010","unstructured":"Xin, W. et al. CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL. Neurology 74, 565\u2013571 (2010).","journal-title":"Neurology"},{"key":"138_CR57","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1212\/01.WNL.0000151974.44980.F1","volume":"64","author":"N Pineda-Trujillo","year":"2005","unstructured":"Pineda-Trujillo, N. et al. A CLN5 mutation causing an atypical neuronal ceroid lipofuscinosis of juvenile onset. Neurology 64, 740\u2013742 (2005).","journal-title":"Neurology"},{"key":"138_CR58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00415-014-7553-y","volume":"262","author":"C Mancini","year":"2015","unstructured":"Mancini, C. et al. Adult-onset autosomal recessive ataxia associated with neuronal ceroid lipofuscinosis type 5 gene (CLN5) mutations. J. Neurol. 262, 173\u2013178 (2015).","journal-title":"J. Neurol."},{"key":"138_CR59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s100480050032","volume":"1","author":"JL Haines","year":"1998","unstructured":"Haines, J. L. et al. Chromosomal localization of two genes underlying late-infantile neuronal ceroid lipofuscinosis. Neurogenetics 1, 217\u2013222 (1998).","journal-title":"Neurogenetics"},{"key":"138_CR60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/brain\/111.1.27","volume":"111","author":"SF Berkovic","year":"1988","unstructured":"Berkovic, S. F., Carpenter, S., Andermann, F., Andermann, E. & Wolfe, L. S. Kufs\u2019 disease: a critical reappraisal. Brain 111, 27\u201362 (1988).","journal-title":"Brain"},{"key":"138_CR61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ymgme.2016.07.011","volume":"119","author":"M Fietz","year":"2016","unstructured":"Fietz, M. et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis. Mol. Genet. Metab. 119, 160\u2013167 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1750-3639.1998.tb00141.x","volume":"8","author":"BD Lake","year":"1998","unstructured":"Lake, B. D., Young, E. P. & Winchester, B. G. Prenatal diagnosis of lysosomal storage diseases. Brain Pathol. 8, 133\u2013149 (1998).","journal-title":"Brain Pathol."},{"key":"138_CR63","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(96)90148-8","volume":"347","author":"PB Munroe","year":"1996","unstructured":"Munroe, P. B. et al. Prenatal diagnosis of Batten\u2019s disease. Lancet 347, 1014\u20131015 (1996).","journal-title":"Lancet"},{"key":"138_CR64","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/pd.1970130907","volume":"13","author":"CW Chow","year":"1993","unstructured":"Chow, C. W., Borg, J., Billson, V. R. & Lake, B. D. Fetal tissue involvement in the late infantile type of neuronal ceroid lipofuscinosis. Prenat. Diagn. 13, 833\u2013841 (1993).","journal-title":"Prenat. Diagn."},{"key":"138_CR65","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00710281","volume":"16","author":"J Rapola","year":"1993","unstructured":"Rapola, J., Salonen, R., Ammala, P. & Santavuori, P. Prenatal diagnosis of infantile neuronal ceroid-lipofuscinosis, INCL: morphological aspects. J. Inherit. Metab. Dis. 16, 349\u2013352 (1993).","journal-title":"J. Inherit. Metab. Dis."},{"key":"138_CR66","first-page":"263","volume":"9","author":"JJ Martin","year":"1974","unstructured":"Martin, J. J. & de Groote, C. Involvement of the skin in late infantile and juvenile amaurotic idiocies (neuronal ceroid-lipofuscinoses). Pathol. Eur. 9, 263\u2013272 (1974).","journal-title":"Pathol. Eur."},{"key":"138_CR67","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0022-510X(84)90082-0","volume":"65","author":"C Ceuterick","year":"1984","unstructured":"Ceuterick, C. & Martin, J. J. Diagnostic role of skin or conjunctival biopsies in neurological disorders. An update. J. Neurol. Sci. 65, 179\u2013191 (1984).","journal-title":"J. Neurol. Sci."},{"key":"138_CR68","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/adc.50.10.753","volume":"50","author":"EM Brett","year":"1975","unstructured":"Brett, E. M. & Lake, B. D. Reassessment of rectal approach to neuropathology in childhood: review of 307 biopsies over 11 years. Arch. Dis. Child 50, 753\u2013762 (1975).","journal-title":"Arch. Dis. Child"},{"key":"138_CR69","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0046-8177(84)80034-9","volume":"15","author":"J Rapola","year":"1984","unstructured":"Rapola, J., Santavuori, P. & Savilahti, E. Suction biopsy of rectal mucosa in the diagnosis of infantile and juvenile types of neuronal ceroid lipofuscinoses. Hum. Pathol. 15, 352\u2013360 (1984).","journal-title":"Hum. Pathol."},{"key":"138_CR70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1750-3639.1998.tb00140.x","volume":"8","author":"C Ceuterick-de Groote","year":"1998","unstructured":"Ceuterick-de Groote, C. & Martin, J. J. Extracerebral biopsy in lysosomal and peroxisomal disorders. Ultrastructural findings. Brain Pathol. 8, 121\u2013132 (1998).","journal-title":"Brain Pathol."},{"key":"138_CR71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1684\/epd.2016.0804","volume":"18","author":"DA Nita","year":"2016","unstructured":"Nita, D. A., Mole, S. E. & Minassian, B. A. Neuronal ceroid lipofuscinoses. Epilept. Disord. 18, 73\u201388 (2016).","journal-title":"Epilept. Disord."},{"key":"138_CR72","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/jcp.2005.027045","volume":"58","author":"G Anderson","year":"2005","unstructured":"Anderson, G., Smith, V. V., Malone, M. & Sebire, N. J. Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre. J. Clin. Pathol. 58, 1305\u20131310 (2005).","journal-title":"J. Clin. Pathol."},{"key":"138_CR73","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/088307389501000602","volume":"10","author":"HH Goebel","year":"1995","unstructured":"Goebel, H. H. The neuronal ceroid-lipofuscinoses. J. Child Neurol. 10, 424\u2013437 (1995).","journal-title":"J. Child Neurol."},{"key":"138_CR74","doi-asserted-by":"crossref","unstructured":"Mole, S. E. & Williams, R. E. Neuronal ceroid-lipofuscinoses. GeneReviews https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1428 (updated 1 Aug 2013).","DOI":"10.1093\/med\/9780199590018.001.0001"},{"key":"138_CR75","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0301-2115(98)00333-9","volume":"281","author":"MA Junaid","year":"1999","unstructured":"Junaid, M. A., Sklower Brooks, S., Wisniewski, K. E. & Pullarkat, R. K. A novel assay for lysosomal pepstatin-insensitive proteinase and its application for the diagnosis of late-infantile neuronal ceroid lipofuscinosis. Clin. Chim. Acta 281, 169\u2013176 (1999).","journal-title":"Clin. Chim. Acta"},{"key":"138_CR76","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/mgme.1999.2809","volume":"66","author":"OP Diggelen van","year":"1999","unstructured":"van Diggelen, O. P. et al. A rapid fluorogenic palmitoyl-protein thioesterase assay: pre- and postnatal diagnosis of INCL. Mol. Genet. Metab. 66, 240\u2013244 (1999).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR77","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/jmg.36.6.471","volume":"36","author":"YV Voznyi","year":"1999","unstructured":"Voznyi, Y. V. et al. A new simple enzyme assay for pre- and postnatal diagnosis of infantile neuronal ceroid lipofuscinosis (INCL) and its variants. J. Med. Genet. 36, 471\u2013474 (1999).","journal-title":"J. Med. Genet."},{"key":"138_CR78","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0014-5793(98)01683-4","volume":"443","author":"DJ Vines","year":"1999","unstructured":"Vines, D. J. & Warburton, M. J. Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I. FEBS Lett. 443, 131\u2013135 (1999).","journal-title":"FEBS Lett."},{"key":"138_CR79","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/clinchem\/46.7.1005","volume":"46","author":"I Sohar","year":"2000","unstructured":"Sohar, I., Lin, L. & Lobel, P. Enzyme-based diagnosis of classical late infantile neuronal ceroid lipofuscinosis: comparison of tripeptidyl peptidase I and pepstatin-insensitive protease assays. Clin. Chem. 46, 1005\u20131008 (2000).","journal-title":"Clin. Chem."},{"key":"138_CR80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1042\/bj20021226","volume":"369","author":"S Partanen","year":"2003","unstructured":"Partanen, S. et al. A replacement of the active-site aspartic acid residue 293 in mouse cathepsin D affects its intracellular stability, processing and transport in HEK-293 cells. Biochem. J. 369, 55\u201362 (2003).","journal-title":"Biochem. J."},{"key":"138_CR81","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","volume":"1852","author":"SE Mole","year":"2015","unstructured":"Mole, S. E. & Cotman, S. L. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim. Biophys. Acta 1852, 2237\u20132241 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"138_CR82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109576","volume":"9","author":"LC Pati\u00f1o","year":"2014","unstructured":"Pati\u00f1o, L. C. et al. Exome sequencing is an efficient tool for variant late-infantile neuronal ceroid lipofuscinosis molecular diagnosis. PLOS ONE 9, e109576 (2014).","journal-title":"PLOS ONE"},{"key":"138_CR83","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF01273267","volume":"42","author":"H Braak","year":"1978","unstructured":"Braak, H. & Goebel, H. H. Loss of pigment-laden stellate cells: a severe alteration of the isocortex in juvenile neuronal ceroid-lipofuscinosis. Acta Neuropathol. 42, 53\u201357 (1978).","journal-title":"Acta Neuropathol."},{"key":"138_CR84","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00684808","volume":"46","author":"H Braak","year":"1979","unstructured":"Braak, H. & Goebel, H. H. Pigmentoarchitectonic pathology of the isocortex in juvenile neuronal ceroid-lipofuscinosis: axonal enlargements in layer IIIab and cell loss in layer V. Acta Neuropathol. 46, 79\u201383 (1979).","journal-title":"Acta Neuropathol."},{"key":"138_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnen\/62.1.1","volume":"62","author":"M Haltia","year":"2003","unstructured":"Haltia, M. The neuronal ceroid-lipofuscinoses. J.\u00a0Neuropathol. Exp. Neurol. 62, 1\u201313 (2003).","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"Suppl. A","key":"138_CR86","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/eipn.2000.0464","volume":"5","author":"M Haltia","year":"2001","unstructured":"Haltia, M., Herva, R., Suopanki, J., Baumann, M. & Tyynela, J. Hippocampal lesions in the neuronal ceroid lipofuscinoses. Eur. J. Paediatr. Neurol. 5 (Suppl. A), 209\u2013211 (2001).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"138_CR87","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1750-3639.2004.tb00077.x","volume":"14","author":"J Tyynela","year":"2004","unstructured":"Tyynela, J., Cooper, J. D., Khan, M. N., Shemilts, S. J. & Haltia, M. Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation. Brain Pathol. 14, 349\u2013357 (2004).","journal-title":"Brain Pathol."},{"key":"138_CR88","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199704000-00005","volume":"56","author":"J Tyynela","year":"1997","unstructured":"Tyynela, J., Suopanki, J., Santavuori, P., Baumann, M. & Haltia, M. Variant late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry. J.\u00a0Neuropathol. Exp. Neurol. 56, 369\u2013375 (1997).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"138_CR89","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/bjo.2006.091637","volume":"90","author":"J Collins","year":"2006","unstructured":"Collins, J., Holder, G. E., Herbert, H. & Adams, G. G. Batten disease: features to facilitate early diagnosis. Br. J. Ophthalmol. 90, 1119\u20131124 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"138_CR90","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bjo.64.10.726","volume":"64","author":"DJ Spalton","year":"1980","unstructured":"Spalton, D. J., Taylor, D. S. & Sanders, M. D. Juvenile Batten\u2019s disease: an ophthalmological assessment of 26 patients. Br. J. Ophthalmol. 64, 726\u2013732 (1980).","journal-title":"Br. J. Ophthalmol."},{"key":"138_CR91","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1006\/mgme.1999.2829","volume":"66","author":"DG Birch","year":"1999","unstructured":"Birch, D. G. Retinal degeneration in retinitis pigmentosa and neuronal ceroid lipofuscinosis: an overview. Mol. Genet. Metab. 66, 356\u2013366 (1999).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR92","first-page":"184","volume":"17","author":"M Elleder","year":"1998","unstructured":"Elleder, M. & Tyynela, J. Incidence of neuronal perikaryal spheroids in neuronal ceroid lipofuscinoses (Batten disease). Clin. Neuropathol. 17, 184\u2013189 (1998).","journal-title":"Clin. Neuropathol."},{"key":"138_CR93","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.bbadis.2015.04.027","volume":"1852","author":"J Carcel-Trullols","year":"2015","unstructured":"Carcel-Trullols, J., Kovacs, A. D. & Pearce, D. A. Cell biology of the NCL proteins: what they do and don\u2019t do. Biochim. Biophys. Acta 1852, 2242\u20132255 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"138_CR94","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.bbadis.2013.01.009","volume":"1832","author":"M Bond","year":"2013","unstructured":"Bond, M., Holthaus, S. M., Tammen, I., Tear, G. & Russell, C. Use of model organisms for the study of neuronal ceroid lipofuscinosis. Biochim. Biophys. Acta 1832, 1842\u20131865 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"138_CR95","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm1595","volume":"13","author":"G Courtine","year":"2007","unstructured":"Courtine, G. et al. Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans? Nat. Med. 13, 561\u2013566 (2007).","journal-title":"Nat. Med."},{"key":"138_CR96","volume":"7","author":"HB Worp van der","year":"2010","unstructured":"van der Worp, H. B. et al. Can animal models of disease reliably inform human studies? PLOS Med. 7, e1000245 (2010).","journal-title":"PLOS Med."},{"key":"138_CR97","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1242\/dmm.018804","volume":"8","author":"AD Kovacs","year":"2015","unstructured":"Kovacs, A. D. & Pearce, D. A. Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender. Dis. Model. Mech. 8, 351\u2013361 (2015).","journal-title":"Dis. Model. Mech."},{"key":"138_CR98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.brainresbull.2012.03.003","volume":"88","author":"JJ Shacka","year":"2012","unstructured":"Shacka, J. J. Mouse models of neuronal ceroid lipofuscinoses: useful pre-clinical tools to delineate disease pathophysiology and validate therapeutics. Brain Res. Bull. 88, 43\u201357 (2012).","journal-title":"Brain Res. Bull."},{"key":"138_CR99","doi-asserted-by":"publisher","DOI":"10.1007\/8904_2018_113","author":"EF Augustine","year":"2018","unstructured":"Augustine, E. F. et al. Short-term administration of mycophenolate is well-tolerated in CLN3 disease (juvenile neuronal ceroid lipofuscinosis). JIMD Rep. https:\/\/doi.org\/10.1007\/8904_2018_113 (2018).","journal-title":"JIMD Rep."},{"key":"138_CR100","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1474-4422(14)70142-5","volume":"13","author":"SW Levin","year":"2014","unstructured":"Levin, S. W. et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol. 13, 777\u2013787 (2014).","journal-title":"Lancet Neurol."},{"key":"138_CR101","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3171\/2013.3.PEDS12397","volume":"11","author":"NR Selden","year":"2013","unstructured":"Selden, N. R. et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J. Neurosurg. Pediatr. 11, 643\u2013652 (2013).","journal-title":"J. Neurosurg. Pediatr."},{"key":"138_CR102","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/0883073813493666","volume":"28","author":"K Weber","year":"2013","unstructured":"Weber, K. & Pearce, D. A. Large animal models for Batten disease: a review. J. Child Neurol. 28, 1123\u20131127 (2013).","journal-title":"J. Child Neurol."},{"key":"138_CR103","unstructured":"Beraldi, R., Mdaki, K., Kovacs, A. D. & Pearce, D. A. Generation of a Juvenile Batten disease porcine model [abstract O15]. Presented at the 15th International Conference of Neuronal Ceroid Lipofuscinosis (Batten disease) in Boston, MA, USA (2016)."},{"key":"138_CR104","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nbd.2018.07.013","volume":"119","author":"JL McBride","year":"2018","unstructured":"McBride, J. L. et al. Discovery of a CLN7 model of Batten disease in non-human primates. Neurobiol. Dis. 119, 65\u201378 (2018).","journal-title":"Neurobiol. Dis."},{"key":"138_CR105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.bbrc.2004.12.038","volume":"327","author":"ML Katz","year":"2005","unstructured":"Katz, M. L. et al. A mutation in the CLN8 gene in English Setter dogs with neuronal ceroid-lipofuscinosis. Biochem. Biophys. Res. Commun. 327, 541\u2013547 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"138_CR106","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygeno.2005.06.005","volume":"86","author":"SA Melville","year":"2005","unstructured":"Melville, S. A. et al. A mutation in canine CLN5 causes neuronal ceroid lipofuscinosis in Border collie dogs. Genomics 86, 287\u2013294 (2005).","journal-title":"Genomics"},{"key":"138_CR107","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.bbadis.2006.09.004","volume":"1762","author":"I Tammen","year":"2006","unstructured":"Tammen, I. et al. A missense mutation (c.184C>T) in ovine CLN6 causes neuronal ceroid lipofuscinosis in\u00a0Merino sheep whereas affected South Hampshire sheep have reduced levels of CLN6 mRNA. Biochim. Biophys. Acta 1762, 898\u2013905 (2006).","journal-title":"Biochim. Biophys. Acta"},{"issue":"Suppl. A","key":"138_CR108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1053\/ejpn.2000.0433","volume":"5","author":"J Tyynela","year":"2001","unstructured":"Tyynela, J. et al. Congenital ovine neuronal ceroid lipofuscinosis \u2014 a cathepsin D deficiency with increased levels of the inactive enzyme. Eur. J. Paediatr. Neurol. 5 (Suppl. A), 43\u201345 (2001).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"138_CR109","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MAT.0b013e31827986fe","volume":"59","author":"X Wei","year":"2013","unstructured":"Wei, X. et al. Initial experience with a juvenile sheep model for evaluation of the pediatric intracorporeal ventricular assist devices [corrected]. ASAIO J. 59, 75\u201380 (2013).","journal-title":"ASAIO J."},{"key":"138_CR110","doi-asserted-by":"crossref","first-page":"R165","DOI":"10.1152\/ajpregu.00163.2017","volume":"315","author":"AJ Sorby-Adams","year":"2018","unstructured":"Sorby-Adams, A. J., Vink, R. & Turner, R. J. Large animal models of stroke and traumatic brain injury as translational tools. Am. J. Physiol. Regul. Integr. Comp. Physiol. 315, R165\u2013R190 (2018).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"138_CR111","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0300985811402846","volume":"49","author":"MM Swindle","year":"2012","unstructured":"Swindle, M. M., Makin, A., Herron, A. J., Clubb, F. J. Jr & Frazier, K. S. Swine as models in biomedical research and toxicology testing. Vet. Pathol. 49, 344\u2013356 (2012).","journal-title":"Vet. Pathol."},{"key":"138_CR112","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajp.22281","volume":"76","author":"KA Phillips","year":"2014","unstructured":"Phillips, K. A. et al. Why primate models matter. Am. J. Primatol. 76, 801\u2013827 (2014).","journal-title":"Am. J. Primatol."},{"key":"138_CR113","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1242\/jeb.02141","volume":"209","author":"J Jelsing","year":"2006","unstructured":"Jelsing, J. et al. The postnatal development of neocortical neurons and glial cells in the Gottingen minipig and the domestic pig brain. J. Exp. Biol. 209, 1454\u20131462 (2006).","journal-title":"J. Exp. Biol."},{"key":"138_CR114","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1046\/j.1525-1373.2000.22314.x","volume":"223","author":"WG Pond","year":"2000","unstructured":"Pond, W. G. et al. Perinatal ontogeny of brain growth in the domestic pig. Proc. Soc. Exp. Biol. Med. 223, 102\u2013108 (2000).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"138_CR115","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1093\/hmg\/ddv356","volume":"24","author":"R Beraldi","year":"2015","unstructured":"Beraldi, R. et al. A novel porcine model of ataxia telangiectasia reproduces neurological features and motor deficits of human disease. Hum. Mol. Genet. 24, 6473\u20136484 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"138_CR116","first-page":"149","volume":"120","author":"MJ Welsh","year":"2009","unstructured":"Welsh, M. J., Rogers, C. S., Stoltz, D. A., Meyerholz, D. K. & Prather, R. S. Development of a porcine model of cystic fibrosis. Trans. Am. Clin. Climatol. Assoc. 120, 149\u2013162 (2009).","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"138_CR117","doi-asserted-by":"crossref","first-page":"29ra31","DOI":"10.1126\/scitranslmed.3000928","volume":"2","author":"DA Stoltz","year":"2010","unstructured":"Stoltz, D. A. et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci. Transl Med. 2, 29ra31 (2010).","journal-title":"Sci. Transl Med."},{"key":"138_CR118","doi-asserted-by":"crossref","first-page":"120402","DOI":"10.1172\/jci.insight.120402","volume":"3","author":"KA White","year":"2018","unstructured":"White, K. A. et al. A porcine model of neurofibromatosis type 1 (NF1) that mimics the human disease. JCI Insight 3, 120402 (2018).","journal-title":"JCI Insight"},{"key":"138_CR119","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/hmg\/11.12.1421","volume":"11","author":"S Chattopadhyay","year":"2002","unstructured":"Chattopadhyay, S. et al. An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum. Mol. Genet. 11, 1421\u20131431 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"138_CR120","first-page":"84","volume":"59","author":"WJ Andrews","year":"1990","unstructured":"Andrews, W. J., Magee, A. G., Gardiner, P. V., Fleming, I. & Morris, T. C. Paroxysmal nocturnal haemoglobinuria and diabetes mellitus. Ulster Med. J. 59, 84\u201386 (1990).","journal-title":"Ulster Med. J."},{"key":"138_CR121","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2012.05.009","volume":"107","author":"J Hu","year":"2012","unstructured":"Hu, J. et al. Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 107, 213\u2013221 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR122","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ymgme.2009.12.002","volume":"99","author":"JY Lu","year":"2010","unstructured":"Lu, J. Y., Hu, J. & Hofmann, S. L. Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 99, 374\u2013378 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR123","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2015.05.005","volume":"116","author":"JY Lu","year":"2015","unstructured":"Lu, J. Y. et al. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 116, 98\u2013105 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR124","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1212\/01.WNL.0000041913.97883.8B","volume":"59","author":"S Chattopadhyay","year":"2002","unstructured":"Chattopadhyay, S., Kriscenski-Perry, E., Wenger, D. A. & Pearce, D. A. An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinoses. Neurology 59, 1816\u20131817 (2002).","journal-title":"Neurology"},{"key":"138_CR125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/mt.2008.9","volume":"16","author":"M Chang","year":"2008","unstructured":"Chang, M. et al. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 16, 649\u2013656 (2008).","journal-title":"Mol. Ther."},{"key":"138_CR126","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.expneurol.2004.03.007","volume":"188","author":"PP Young","year":"2004","unstructured":"Young, P. P., Fantz, C. R. & Sands, M. S. VEGF disrupts the neonatal blood-brain barrier and increases life span after non-ablative BMT in a murine model of congenital neurodegeneration caused by a lysosomal enzyme deficiency. Exp. Neurol. 188, 104\u2013114 (2004).","journal-title":"Exp. Neurol."},{"key":"138_CR127","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1073\/pnas.78.9.5838","volume":"78","author":"EA Neuwelt","year":"1981","unstructured":"Neuwelt, E. A. et al. Delivery of hexosaminidase A to the cerebrum after osmotic modification of the blood\u2014brain barrier. Proc. Natl Acad. Sci. USA 78, 5838\u20135841 (1981).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"138_CR128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva, C. et al. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J. Control. Release 235, 34\u201347 (2016).","journal-title":"J. Control. Release"},{"key":"138_CR129","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fncel.2014.00362","volume":"8","author":"AC Fonseca da","year":"2014","unstructured":"da Fonseca, A. C. et al. The impact of microglial activation on blood-brain barrier in brain diseases. Front. Cell. Neurosci. 8, 362 (2014).","journal-title":"Front. Cell. Neurosci."},{"key":"138_CR130","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/j.1471-4159.2007.04567.x","volume":"101","author":"I Rite","year":"2007","unstructured":"Rite, I., Machado, A., Cano, J. & Venero, J. L. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J. Neurochem. 101, 1567\u20131582 (2007).","journal-title":"J. Neurochem."},{"key":"138_CR131","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ymgme.2014.09.004","volume":"114","author":"BR Vuillemenot","year":"2015","unstructured":"Vuillemenot, B. R. et al. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 114, 281\u2013293 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR132","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT01907087 (2018)."},{"key":"138_CR133","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz, A. et al. Study of intraventricular cerliponase alfa for CLN2 disease. N. Engl. J. Med. 378, 1898\u20131907 (2018).","journal-title":"N. Engl. J. Med."},{"key":"138_CR134","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT02485899 (2018)."},{"key":"138_CR135","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT02678689 (2018)."},{"key":"138_CR136","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT02963350 (2017)."},{"key":"138_CR137","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","volume":"69","author":"S Worgall","year":"2007","unstructured":"Worgall, S. et al. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology 69, 521 (2007).","journal-title":"Neurology"},{"key":"138_CR138","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.3174\/ajnr.A4816","volume":"37","author":"U Lobel","year":"2016","unstructured":"Lobel, U. et al. Volumetric description of brain atrophy in neuronal ceroid lipofuscinosis 2: supratentorial gray matter shows uniform disease progression. AJNR Am. J. Neuroradiol. 37, 1938\u20131943 (2016).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"138_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT00976352 (2018)."},{"key":"138_CR140","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT01474343 (2014)."},{"key":"138_CR141","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT02053064 (2017)."},{"key":"138_CR142","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT02716246 (2018)."},{"key":"138_CR143","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2017.12.434","volume":"123","author":"K Sawamoto","year":"2018","unstructured":"Sawamoto, K., Chen, H. H., Almeciga-Diaz, C. J., Mason, R. W. & Tomatsu, S. Gene therapy for mucopolysaccharidoses. Mol. Genet. Metab. 123, 59\u201368 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR144","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella, P., Ronzitti, G. & Mingozzi, F. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 8, 87\u2013104 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"138_CR145","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fnmol.2014.00076","volume":"7","author":"G Murlidharan","year":"2014","unstructured":"Murlidharan, G., Samulski, R. J. & Asokan, A. Biology of adeno-associated viral vectors in the central nervous system. Front. Mol. Neurosci. 7, 76 (2014).","journal-title":"Front. Mol. Neurosci."},{"key":"138_CR146","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.nbd.2004.03.005","volume":"16","author":"M Griffey","year":"2004","unstructured":"Griffey, M. et al. Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16, 360\u2013369 (2004).","journal-title":"Neurobiol. Dis."},{"key":"138_CR147","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ymthe.2005.11.008","volume":"13","author":"MA Griffey","year":"2006","unstructured":"Griffey, M. A. et al. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol. Ther. 13, 538\u2013547 (2006).","journal-title":"Mol. Ther."},{"key":"138_CR148","doi-asserted-by":"crossref","first-page":"313ra180","DOI":"10.1126\/scitranslmed.aac6191","volume":"7","author":"ML Katz","year":"2015","unstructured":"Katz, M. L. et al. AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease. Sci. Transl Med. 7, 313ra180 (2015).","journal-title":"Sci. Transl Med."},{"key":"138_CR149","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1128\/JVI.77.12.6995-7006.2003","volume":"77","author":"SR Opie","year":"2003","unstructured":"Opie, S. R. et al. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77, 6995\u20137006 (2003).","journal-title":"J. Virol."},{"key":"138_CR150","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/sj.mt.6300249","volume":"15","author":"MA Cabrera-Salazar","year":"2007","unstructured":"Cabrera-Salazar, M. A. et al. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol. Ther. 15, 1782\u20131788 (2007).","journal-title":"Mol. Ther."},{"key":"138_CR151","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.mt.6300049","volume":"15","author":"D Sondhi","year":"2007","unstructured":"Sondhi, D. et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol. Ther. 15, 481\u2013491 (2007).","journal-title":"Mol. Ther."},{"key":"138_CR152","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1128\/JVI.03371-13","volume":"88","author":"M Mietzsch","year":"2014","unstructured":"Mietzsch, M., Broecker, F., Reinhardt, A., Seeberger, P. H. & Heilbronn, R. Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans. J. Virol. 88, 2991\u20133003 (2014).","journal-title":"J. Virol."},{"key":"138_CR153","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hum.2012.253","volume":"25","author":"D Sondhi","year":"2014","unstructured":"Sondhi, D. et al. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. Hum. Gene Ther. 25, 223\u2013239 (2014).","journal-title":"Hum. Gene Ther."},{"key":"138_CR154","doi-asserted-by":"crossref","first-page":"13077","DOI":"10.1523\/JNEUROSCI.2518-14.2014","volume":"34","author":"SL Macauley","year":"2014","unstructured":"Macauley, S. L. et al. An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J. Neurosci. 34, 13077\u201313082 (2014).","journal-title":"J. Neurosci."},{"key":"138_CR155","doi-asserted-by":"crossref","first-page":"E5920","DOI":"10.1073\/pnas.1701832114","volume":"114","author":"C Shyng","year":"2017","unstructured":"Shyng, C. et al. Synergistic effects of treating the spinal cord and brain in CLN1 disease. Proc. Natl Acad. Sci. USA 114, E5920\u2013E5929 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"138_CR156","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.ymthe.2018.02.027","volume":"26","author":"SM Kleine Holthaus","year":"2018","unstructured":"Kleine Holthaus, S. M. et al. Prevention of photoreceptor cell loss in a Cln6nclf mouse model of Batten disease requires CLN6 gene transfer to bipolar cells. Mol. Ther. 26, 1343\u20131353 (2018).","journal-title":"Mol. Ther."},{"key":"138_CR157","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1093\/hmg\/11.22.2709","volume":"11","author":"SL Cotman","year":"2002","unstructured":"Cotman, S. L. et al. Cln3(Deltaex7\/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum. Mol. Genet. 11, 2709\u20132721 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"138_CR158","doi-asserted-by":"crossref","first-page":"9669","DOI":"10.1523\/JNEUROSCI.1635-16.2016","volume":"36","author":"ME Bosch","year":"2016","unstructured":"Bosch, M. E. et al. Self-complementary AAV9 gene delivery partially corrects pathology associated with juvenile neuronal ceroid lipofuscinosis (CLN3). J. Neurosci. 36, 9669\u20139682 (2016).","journal-title":"J. Neurosci."},{"key":"138_CR159","unstructured":"Cain, J. T. et al. Testing safety and efficacy of AAV9-CLN6 gene therapy in a mouse model of CLN6-Batten disease [P11]. Presented at the 15th International Conference of Neuronal Ceroid Lipofuscinosis (Batten disease) in Boston, MA, USA (2016)."},{"key":"138_CR160","unstructured":"Likhite, S. et al. Gene therapy for the CLN6 Batten disease: in vivo validation and safety study into a non-human primate model [P48]. Presented at the 15th International Conference of Neuronal Ceroid Lipofuscinosis (Batten disease) in Boston, MA, USA (2016)."},{"key":"138_CR161","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT02725580 (2018)."},{"key":"138_CR162","unstructured":"Johnson T. B. et al. Intrathecal scAAV9-CLN3 administration: potential gene therapy for CLN3-Batten disease [abstract]. Presented at the 16th International Conference on Neuronal Ceroid Lipofuscinosis (2018)."},{"key":"138_CR163","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/ct2\/show\/NCT03770572 (2018)."},{"key":"138_CR164","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT00151216 (2018)."},{"key":"138_CR165","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","volume":"19","author":"S Worgall","year":"2008","unstructured":"Worgall, S. et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19, 463\u2013474 (2008).","journal-title":"Hum. Gene Ther."},{"key":"138_CR166","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT01161576 (2018)."},{"key":"138_CR167","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT01414985 (2018)."},{"key":"138_CR168","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/hum.2016.049","volume":"27","author":"LA Wiley","year":"2016","unstructured":"Wiley, L. A. et al. Using patient-specific induced pluripotent stem cells and wild-type mice to develop a gene augmentation-based strategy to treat CLN3-associated retinal degeneration. Hum. Gene Ther. 27, 835\u2013846 (2016).","journal-title":"Hum. Gene Ther."},{"key":"138_CR169","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.preteyeres.2004.08.002","volume":"24","author":"A Wenzel","year":"2005","unstructured":"Wenzel, A., Grimm, C., Samardzija, M. & Reme, C. E. Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration. Prog. Retin. Eye Res. 24, 275\u2013306 (2005).","journal-title":"Prog. Retin. Eye Res."},{"key":"138_CR170","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.preteyeres.2011.11.005","volume":"31","author":"R Wen","year":"2012","unstructured":"Wen, R., Tao, W., Li, Y. & Sieving, P. A. CNTF and retina. Prog. Retin. Eye Res. 31, 136\u2013151 (2012).","journal-title":"Prog. Retin. Eye Res."},{"key":"138_CR171","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127204","volume":"10","author":"W Jankowiak","year":"2015","unstructured":"Jankowiak, W. et al. Sustained neural stem cell-based intraocular delivery of CNTF attenuates photoreceptor loss in the nclf mouse model of neuronal ceroid lipofuscinosis. PLOS ONE 10, e0127204 (2015).","journal-title":"PLOS ONE"},{"key":"138_CR172","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.exer.2016.09.003","volume":"152","author":"CJ Tracy","year":"2016","unstructured":"Tracy, C. J. et al. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis. Exp. Eye Res. 152, 77\u201387 (2016).","journal-title":"Exp. Eye Res."},{"key":"138_CR173","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT00337636 (2015)."},{"key":"138_CR174","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1034\/j.1600-0854.2002.31102.x","volume":"3","author":"P Arvan","year":"2002","unstructured":"Arvan, P., Zhao, X., Ramos-Castaneda, J. & Chang, A. Secretory pathway quality control operating in Golgi, plasmalemmal, and endosomal systems. Traffic 3, 771\u2013780 (2002).","journal-title":"Traffic"},{"key":"138_CR175","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0955-0674(00)00233-7","volume":"13","author":"L Ellgaard","year":"2001","unstructured":"Ellgaard, L. & Helenius, A. ER quality control: towards an understanding at the molecular level. Curr. Opin. Cell Biol. 13, 431\u2013437 (2001).","journal-title":"Curr. Opin. Cell Biol."},{"key":"138_CR176","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/emmm.200900036","volume":"1","author":"G Parenti","year":"2009","unstructured":"Parenti, G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol. Med. 1, 268\u2013279 (2009).","journal-title":"EMBO Mol. Med."},{"key":"138_CR177","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","volume":"9","author":"KJ Valenzano","year":"2011","unstructured":"Valenzano, K. J. et al. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev. Technol. 9, 213\u2013235 (2011).","journal-title":"Assay Drug Dev. Technol."},{"key":"138_CR178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/BC.2008.009","volume":"389","author":"JQ Fan","year":"2008","unstructured":"Fan, J. Q. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol. Chem. 389, 1\u201311 (2008).","journal-title":"Biol. Chem."},{"key":"138_CR179","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbrc.2010.03.137","volume":"395","author":"G Dawson","year":"2010","unstructured":"Dawson, G., Schroeder, C. & Dawson, P. E. Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem. Biophys. Res. Commun. 395, 66\u201369 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"138_CR180","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/humu.21624","volume":"33","author":"M Kousi","year":"2012","unstructured":"Kousi, M., Lehesjoki, A. E. & Mole, S. E. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum. Mutat. 33, 42\u201363 (2012).","journal-title":"Hum. Mutat."},{"key":"138_CR181","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","volume":"113","author":"B Roy","year":"2016","unstructured":"Roy, B. et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc. Natl Acad. Sci. USA 113, 12508\u201312513 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"Suppl. A","key":"138_CR182","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/ejpn.2000.0436","volume":"5","author":"DE Sleat","year":"2001","unstructured":"Sleat, D. E., Sohar, I., Gin, R. M. & Lobel, P. Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur. J. Paediatr. Neurol. 5 (Suppl. A), 57\u201362 (2001).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"138_CR183","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1093\/hmg\/ddt120","volume":"22","author":"JN Miller","year":"2013","unstructured":"Miller, J. N., Chan, C. H. & Pearce, D. A. The role of nonsense-mediated decay in neuronal ceroid lipofuscinosis. Hum. Mol. Genet. 22, 2723\u20132734 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"138_CR184","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","volume":"94","author":"KM Schoch","year":"2017","unstructured":"Schoch, K. M. & Miller, T. M. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron 94, 1056\u20131070 (2017).","journal-title":"Neuron"},{"key":"138_CR185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fnmol.2017.00263","volume":"10","author":"N Ramesh","year":"2017","unstructured":"Ramesh, N. & Pandey, U. B. Autophagy Dysregulation in ALS: when protein aggregates get out of hand. Front. Mol. Neurosci. 10, 263 (2017).","journal-title":"Front. Mol. Neurosci."},{"key":"138_CR186","doi-asserted-by":"crossref","first-page":"04","DOI":"10.3389\/fnagi.2018.00004","volume":"10","author":"MS Uddin","year":"2018","unstructured":"Uddin, M. S. et al. Autophagy and Alzheimer\u2019s disease: from molecular mechanisms to therapeutic implications. Front. Aging Neurosci. 10, 04 (2018).","journal-title":"Front. Aging Neurosci."},{"key":"138_CR187","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40035-016-0065-1","volume":"5","author":"B Wang","year":"2016","unstructured":"Wang, B., Abraham, N., Gao, G. & Yang, Q. Dysregulation of autophagy and mitochondrial function in Parkinson\u2019s disease. Transl Neurodegener. 5, 19 (2016).","journal-title":"Transl Neurodegener."},{"key":"138_CR188","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0002-9440(10)61253-9","volume":"167","author":"M Koike","year":"2005","unstructured":"Koike, M. et al. Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am. J. Pathol. 167, 1713\u20131728 (2005).","journal-title":"Am. J. Pathol."},{"key":"138_CR189","doi-asserted-by":"crossref","first-page":"20483","DOI":"10.1074\/jbc.M602180200","volume":"281","author":"Y Cao","year":"2006","unstructured":"Cao, Y. et al. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J. Biol. Chem. 281, 20483\u201320493 (2006).","journal-title":"J. Biol. Chem."},{"key":"138_CR190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2217\/clp.11.70","volume":"7","author":"SL Cotman","year":"2012","unstructured":"Cotman, S. L. & Staropoli, J. F. The juvenile Batten disease protein, CLN3, and its role in regulating anterograde and retrograde post-Golgi trafficking. Clin. Lipidol. 7, 79\u201391 (2012).","journal-title":"Clin. Lipidol."},{"key":"138_CR191","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature09204","volume":"466","author":"C Behrends","year":"2010","unstructured":"Behrends, C., Sowa, M. E., Gygi, S. P. & Harper, J. W. Network organization of the human autophagy system. Nature 466, 68\u201376 (2010).","journal-title":"Nature"},{"key":"138_CR192","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11626-015-9979-7","volume":"52","author":"M Hong","year":"2016","unstructured":"Hong, M. et al. Fibrates inhibit the apoptosis of Batten disease lymphoblast cells via autophagy recovery and regulation of mitochondrial membrane potential. In\u00a0Vitro Cell. Dev. Biol. Anim. 52, 349\u2013355 (2016).","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"138_CR193","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0197-0186(01)00052-3","volume":"39","author":"CK Combs","year":"2001","unstructured":"Combs, C. K., Bates, P., Karlo, J. C. & Landreth, G. E. Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem. Int. 39, 449\u2013457 (2001).","journal-title":"Neurochem. Int."},{"key":"138_CR194","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1523\/JNEUROSCI.23-15-06264.2003","volume":"23","author":"D Deplanque","year":"2003","unstructured":"Deplanque, D. et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23, 6264\u20136271 (2003).","journal-title":"J. Neurosci."},{"key":"138_CR195","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/jnc.13987","volume":"141","author":"A Ghosh","year":"2017","unstructured":"Ghosh, A., Rangasamy, S. B., Modi, K. K. & Pahan, K. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J. Neurochem. 141, 423\u2013435 (2017).","journal-title":"J. Neurochem."},{"key":"138_CR196","doi-asserted-by":"crossref","first-page":"10309","DOI":"10.1074\/jbc.M114.610659","volume":"290","author":"A Ghosh","year":"2015","unstructured":"Ghosh, A. et al. Activation of peroxisome proliferator-activated receptor alpha induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders. J. Biol. Chem. 290, 10309\u201310324 (2015).","journal-title":"J. Biol. Chem."},{"key":"138_CR197","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","volume":"325","author":"M Sardiello","year":"2009","unstructured":"Sardiello, M. et al. A gene network regulating lysosomal biogenesis and function. Science 325, 473\u2013477 (2009).","journal-title":"Science"},{"key":"138_CR198","volume":"8","author":"M Palmieri","year":"2017","unstructured":"Palmieri, M. et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat. Commun. 8, 14338 (2017).","journal-title":"Nat. Commun."},{"key":"138_CR199","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.cellsig.2014.08.019","volume":"26","author":"D Heras-Sandoval","year":"2014","unstructured":"Heras-Sandoval, D., Perez-Rojas, J. M., Hernandez-Damian, J. & Pedraza-Chaverri, J. The role of PI3K\/AKT\/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 26, 2694\u20132701 (2014).","journal-title":"Cell Signal."},{"key":"138_CR200","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/8904_2013_226","volume":"11","author":"M Gavin","year":"2013","unstructured":"Gavin, M. et al. Substrate reduction therapy in four patients with milder CLN1 mutations and juvenile-onset Batten disease using cysteamine bitartrate. JIMD Rep. 11, 87\u201392 (2013).","journal-title":"JIMD Rep."},{"key":"138_CR201","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT00028262 (2016)."},{"key":"138_CR202","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/brain\/awt020","volume":"136","author":"J Groh","year":"2013","unstructured":"Groh, J. et al. Immune cells perturb axons and impair neuronal survival in a mouse model of infantile neuronal ceroid lipofuscinosis. Brain 136, 1083\u20131101 (2013).","journal-title":"Brain"},{"key":"138_CR203","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/glia.22962","volume":"64","author":"J Groh","year":"2016","unstructured":"Groh, J. et al. Sialoadhesin promotes neuroinflammation-related disease progression in two mouse models of CLN disease. Glia 64, 792\u2013809 (2016).","journal-title":"Glia"},{"key":"138_CR204","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/01.WNL.0000151973.08426.7E","volume":"64","author":"D Ramirez-Montealegre","year":"2005","unstructured":"Ramirez-Montealegre, D. et al. Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Neurology 64, 743\u2013745 (2005).","journal-title":"Neurology"},{"key":"138_CR205","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.nbd.2007.08.007","volume":"29","author":"JA Castaneda","year":"2008","unstructured":"Castaneda, J. A. & Pearce, D. A. Identification of alpha-fetoprotein as an autoantigen in juvenile Batten disease. Neurobiol. Dis. 29, 92\u2013102 (2008).","journal-title":"Neurobiol. Dis."},{"key":"138_CR206","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.autrev.2016.07.022","volume":"15","author":"A Virgilio De","year":"2016","unstructured":"De Virgilio, A. et al. Parkinson\u2019s disease: autoimmunity and neuroinflammation. Autoimmun. Rev. 15, 1005\u20131011 (2016).","journal-title":"Autoimmun. Rev."},{"key":"138_CR207","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3389\/fneur.2017.00486","volume":"8","author":"SI Khalid","year":"2017","unstructured":"Khalid, S. I., Ampie, L., Kelly, R., Ladha, S. S. & Dardis, C. Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials. Front. Neurol. 8, 486 (2017).","journal-title":"Front. Neurol."},{"key":"138_CR208","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3233\/JAD-160488","volume":"54","author":"PL McGeer","year":"2016","unstructured":"McGeer, P. L., Rogers, J., McGeer & Inflammation, E. G. Antiinflammatory agents, and Alzheimer\u2019s disease: the last 22 years. J. Alzheimers Dis. 54, 853\u2013857 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"138_CR209","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2016.07.003","volume":"61","author":"EE Spangenberg","year":"2017","unstructured":"Spangenberg, E. E. & Green, K. N. Inflammation in Alzheimer\u2019s disease: lessons learned from microglia-depletion models. Brain Behav. Immun. 61, 1\u201311 (2017).","journal-title":"Brain Behav. Immun."},{"key":"138_CR210","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12974-015-0366-9","volume":"12","author":"NN Dagher","year":"2015","unstructured":"Dagher, N. N. et al. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J. Neuroinflamm. 12, 139 (2015).","journal-title":"J. Neuroinflamm."},{"key":"138_CR211","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jneuroim.2010.08.024","volume":"230","author":"SS Seehafer","year":"2011","unstructured":"Seehafer, S. S. et al. Immunosuppression alters disease severity in juvenile Batten disease mice. J. Neuroimmunol. 230, 169\u2013172 (2011).","journal-title":"J. Neuroimmunol."},{"key":"138_CR212","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/show\/NCT01399047 (2017)."},{"key":"138_CR213","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883\u2013897 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"138_CR214","first-page":"213","volume":"12","author":"J Chun","year":"2011","unstructured":"Chun, J. & Brinkmann, V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov. Med. 12, 213\u2013228 (2011).","journal-title":"Discov. Med."},{"key":"138_CR215","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/cei.12195","volume":"175","author":"N Melzer","year":"2014","unstructured":"Melzer, N. & Meuth, S. G. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clin. Exp. Immunol. 175, 359\u2013372 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"138_CR216","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.ymthe.2017.04.021","volume":"25","author":"J Groh","year":"2017","unstructured":"Groh, J., Berve, K. & Martini, R. Fingolimod and teriflunomide attenuate neurodegeneration in mouse models of neuronal ceroid lipofuscinosis. Mol. Ther. 25, 1889\u20131899 (2017).","journal-title":"Mol. Ther."},{"key":"138_CR217","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/01.wnl.0000307753.88839.29","volume":"70","author":"L Aberg","year":"2008","unstructured":"Aberg, L. et al. Intermittent prednisolone and autoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinosis. Neurology 70, 1218\u20131220 (2008).","journal-title":"Neurology"},{"key":"138_CR218","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jnr.20685","volume":"82","author":"I Ahmad","year":"2005","unstructured":"Ahmad, I. et al. Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice. J.\u00a0Neurosci. Res. 82, 811\u2013821 (2005).","journal-title":"J. Neurosci. Res."},{"key":"138_CR219","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.brainresrev.2007.05.012","volume":"57","author":"SH Mellon","year":"2008","unstructured":"Mellon, S. H., Gong, W. & Schonemann, M. D. Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res. Rev. 57, 410\u2013420 (2008).","journal-title":"Brain Res. Rev."},{"key":"138_CR220","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","volume":"21","author":"EKM Reeves","year":"2013","unstructured":"Reeves, E. K. M., Hoffman, E. P., Nagaraju, K., Damsker, J. M. & McCall, J. M. VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg. Med. Chem. 21, 2241\u20132249 (2013).","journal-title":"Bioorg. Med. Chem."},{"key":"138_CR221","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ana.24815","volume":"80","author":"A Aldrich","year":"2016","unstructured":"Aldrich, A. et al. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3). Ann. Neurol. 80, 909\u2013923 (2016).","journal-title":"Ann. Neurol."},{"key":"138_CR222","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/imm.12233","volume":"142","author":"S Amor","year":"2014","unstructured":"Amor, S. et al. Inflammation in neurodegenerative diseases\u2014an update. Immunology 142, 151\u2013166 (2014).","journal-title":"Immunology"},{"key":"138_CR223","first-page":"188","volume":"56","author":"MA Osuna-Zazuetal","year":"2015","unstructured":"Osuna-Zazuetal, M. A., Ponce-Gomez, J. A. & Perez-Neri, I. Neuroprotective mechanisms of cannabinoids in brain ischemia and neurodegenerative disorders [Spanish]. Invest. Clin. 56, 188\u2013200 (2015).","journal-title":"Invest. Clin."},{"key":"138_CR224","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jphs.2014.12.005","volume":"127","author":"L Nguyen","year":"2015","unstructured":"Nguyen, L. et al. Role of sigma-1 receptors in neurodegenerative diseases. J. Pharmacol. Sci. 127, 17\u201329 (2015).","journal-title":"J. Pharmacol. Sci."},{"key":"138_CR225","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/aps.2009.24","volume":"30","author":"XX Dong","year":"2009","unstructured":"Dong, X. X., Wang, Y. & Qin, Z. H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 30, 379\u2013387 (2009).","journal-title":"Acta Pharmacol. Sin."},{"key":"138_CR226","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2174\/1568007043336761","volume":"3","author":"G Benitez-King","year":"2004","unstructured":"Benitez-King, G., Ramirez-Rodriguez, G., Ortiz, L. & Meza, I. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 3, 515\u2013533 (2004).","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"138_CR227","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5607\/en.2015.24.4.325","volume":"24","author":"GH Kim","year":"2015","unstructured":"Kim, G. H., Kim, J. E., Rhie, S. J. & Yoon, S. The role of oxidative stress in neurodegenerative diseases. Exp. Neurobiol. 24, 325\u2013340 (2015).","journal-title":"Exp. Neurobiol."},{"key":"138_CR228","doi-asserted-by":"crossref","DOI":"10.1038\/srep04874","volume":"4","author":"SS Karuppagounder","year":"2014","unstructured":"Karuppagounder, S. S. et al. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease. Sci. Rep. 4, 4874 (2014).","journal-title":"Sci. Rep."},{"key":"138_CR229","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-017-0050-3","volume":"8","author":"S Zhang","year":"2017","unstructured":"Zhang, S., Tang, M. B., Luo, H. Y., Shi, C. H. & Xu, Y. M. Necroptosis in neurodegenerative diseases: a potential therapeutic target. Cell Death Dis. 8, e2905 (2017).","journal-title":"Cell Death Dis."},{"key":"138_CR230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.neuropharm.2010.10.010","volume":"60","author":"AD Kovacs","year":"2010","unstructured":"Kovacs, A. D. et al. Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease. Neuropharmacology 60, 405\u2013409 (2010).","journal-title":"Neuropharmacology"},{"key":"138_CR231","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2007.09.012","volume":"209","author":"AD Kovacs","year":"2008","unstructured":"Kovacs, A. D. & Pearce, D. A. Attenuation of AMPA receptor activity improves motor skills in a mouse model of juvenile Batten disease. Exp. Neurol. 209, 288\u2013291 (2008).","journal-title":"Exp. Neurol."},{"key":"138_CR232","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/nn.3526","volume":"16","author":"C Sarkar","year":"2013","unstructured":"Sarkar, C. et al. Neuroprotection and lifespan extension in Ppt1(\u2212\/\u2212) mice by NtBuHA: therapeutic implications for INCL. Nat. Neurosci. 16, 1608\u20131617 (2013).","journal-title":"Nat. Neurosci."},{"key":"138_CR233","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.10143","volume":"51","author":"S Dhar","year":"2002","unstructured":"Dhar, S. et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann. Neurol. 51, 448\u2013466 (2002).","journal-title":"Ann. Neurol."},{"key":"138_CR234","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.ymgme.2017.12.066","volume":"123","author":"J Cooper","year":"2018","unstructured":"Cooper, J. et al. Testing combinatorial therapies for juvenile Batten disease. Mol. Genet. Metab. 123, S33 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR235","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.23545","volume":"71","author":"SL Macauley","year":"2012","unstructured":"Macauley, S. L. et al. Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. Ann. Neurol. 71, 797\u2013804 (2012).","journal-title":"Ann. Neurol."},{"key":"138_CR236","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1073\/pnas.0500055102","volume":"102","author":"N Agrawal","year":"2005","unstructured":"Agrawal, N. et al. Identification of combinatorial drug regimens for treatment of Huntington\u2019s disease using Drosophila. Proc. Natl Acad. Sci. USA 102, 3777\u20133781 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"138_CR237","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"28","author":"EF Augustine","year":"2013","unstructured":"Augustine, E. F., Adams, H. R. & Mink, J. W. Clinical trials in rare disease: challenges and opportunities. J.\u00a0Child Neurol. 28, 1142\u20131150 (2013).","journal-title":"J. Child Neurol."},{"key":"138_CR238","volume":"13","author":"D Timm","year":"2018","unstructured":"Timm, D. et al. Searching for novel biomarkers using a mouse model of CLN3-Batten disease. PLOS ONE 13, e0201470 (2018).","journal-title":"PLOS ONE"},{"key":"138_CR239","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/febs.13593","volume":"283","author":"SL Hersrud","year":"2016","unstructured":"Hersrud, S. L., Geraets, R. D., Weber, K. L., Chan, C. H. & Pearce, D. A. Plasma biomarkers for neuronal ceroid lipofuscinosis. FEBS J. 283, 459\u2013471 (2016).","journal-title":"FEBS J."},{"key":"138_CR240","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.chest.2017.12.018","volume":"153","author":"JK Stoller","year":"2018","unstructured":"Stoller, J. K. The challenge of rare diseases. Chest 153, 1309\u20131314 (2018).","journal-title":"Chest"},{"key":"138_CR241","unstructured":"US Department of Health & Human Services. Developing products for rare diseases & conditions. FDA.gov https:\/\/www.fda.gov\/ForIndustry\/ucm2005525.htm (updated 10 May 2018)."},{"key":"138_CR242","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1212\/WNL.0b013e3182377e29","volume":"77","author":"J Cialone","year":"2011","unstructured":"Cialone, J. et al. Quantitative telemedicine ratings in Batten disease: implications for rare disease research. Neurology 77, 1808\u20131811 (2011).","journal-title":"Neurology"},{"key":"138_CR243","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1212\/01.wnl.0000169019.41332.8a","volume":"65","author":"FJ Marshall","year":"2005","unstructured":"Marshall, F. J. et al. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology 65, 275\u2013279 (2005).","journal-title":"Neurology"},{"key":"138_CR244","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1090-3798(15)30049-0","volume":"19","author":"A Schulz","year":"2015","unstructured":"Schulz, A. et al. The DEM-CHILD NCL patient database: a tool for the evaluation of therapies in neuronal ceroid lipofuscinoses (NCL). Eur. J. Paediatr. Neurol. 19, S16 (2015).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"138_CR245","unstructured":"Sanford Research. Welcome to the Coordination of Rare Diseases at Sanford (CoRDS)! Sanford Research http:\/\/www.sanfordresearch.org\/SpecialPrograms\/cords\/ (2018)."},{"key":"138_CR246","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2004-815788","volume":"35","author":"SL Vanhanen","year":"2004","unstructured":"Vanhanen, S. L. et al. Neuroradiological findings (MRS, MRI, SPECT) in infantile neuronal ceroid-lipofuscinosis (infantile CLN1) at different stages of the disease. Neuropediatrics 35, 27\u201335 (2004).","journal-title":"Neuropediatrics"},{"key":"138_CR247","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/088307389501000604","volume":"10","author":"SL Vanhanen","year":"1995","unstructured":"Vanhanen, S. L., Raininko, R., Autti, T. & Santavuori, P. MRI evaluation of the brain in infantile neuronal ceroid-lipofuscinosis. Part 2: MRI findings in 21 patients. J. Child Neurol. 10, 444\u2013450 (1995).","journal-title":"J. Child Neurol."},{"key":"138_CR248","first-page":"1443","volume":"15","author":"SL Vanhanen","year":"1994","unstructured":"Vanhanen, S. L., Raininko, R. & Santavuori, P. Early differential diagnosis of infantile neuronal ceroid lipofuscinosis, Rett syndrome, and Krabbe disease by CT and MR. AJNR Am. J. Neuroradiol. 15, 1443\u20131453 (1994).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"138_CR249","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/088307389501000603","volume":"10","author":"SL Vanhanen","year":"1995","unstructured":"Vanhanen, S. L., Raininko, R., Santavuori, P., Autti, T. & Haltia, M. MRI evaluation of the brain in infantile neuronal ceroid-lipofuscinosis. Part 1: postmortem MRI with histopathologic correlation. J. Child Neurol. 10, 438\u2013443 (1995).","journal-title":"J. Child Neurol."},{"key":"138_CR250","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1469-8749.1997.tb07465.x","volume":"39","author":"SL Vanhanen","year":"1997","unstructured":"Vanhanen, S. L., Sainio, K., Lappi, M. & Santavuori, P. EEG and evoked potentials in infantile neuronal ceroid-lipofuscinosis. Dev. Med. Child Neurol. 39, 456\u2013463 (1997).","journal-title":"Dev. Med. Child Neurol."},{"key":"138_CR251","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0387-7604(01)00231-5","volume":"23","author":"E Veneselli","year":"2001","unstructured":"Veneselli, E., Biancheri, R., Buoni, S. & Fois, A. Clinical and EEG findings in 18 cases of late infantile neuronal ceroid lipofuscinosis. Brain Dev. 23, 306\u2013311 (2001).","journal-title":"Brain Dev."},{"key":"138_CR252","first-page":"12","volume":"54","author":"BF Westmoreland","year":"1979","unstructured":"Westmoreland, B. F., Groover, R. V. & Sharbrough, F. W. Electrographic findings in three types of cerebromacular degeneration. Mayo Clin. Proc. 54, 12\u201321 (1979).","journal-title":"Mayo Clin. Proc."},{"key":"138_CR253","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF00710254","volume":"16","author":"A Kohlschutter","year":"1993","unstructured":"Kohlschutter, A., Gardiner, R. M. & Goebel, H. H. Human forms of neuronal ceroid-lipofuscinosis (Batten disease): consensus on diagnostic criteria, Hamburg 1992. J. Inherit. Metab. Dis. 16, 241\u2013244 (1993).","journal-title":"J. Inherit. Metab. Dis."},{"key":"138_CR254","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3174\/ajnr.A4978","volume":"38","author":"EH Baker","year":"2017","unstructured":"Baker, E. H., Levin, S. W., Zhang, Z. & Mukherjee, A. B. MRI brain volume measurements in infantile neuronal ceroid lipofuscinosis. AJNR Am. J. Neuroradiol. 38, 376\u2013382 (2017).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"138_CR255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1469-8749.1992.tb08564.x","volume":"34","author":"P Santavuori","year":"1992","unstructured":"Santavuori, P., Raininko, R., Vanhanen, S. L., Launes, J. & Sainio, K. MRI of the brain, EEG sleep spindles and SPECT in the early diagnosis of infantile neuronal ceroid lipofuscinosis. Dev. Med. Child Neurol. 34, 61\u201365 (1992).","journal-title":"Dev. Med. Child Neurol."},{"key":"138_CR256","first-page":"1373","volume":"19","author":"D Seitz","year":"1998","unstructured":"Seitz, D. et al. MR imaging and localized proton MR spectroscopy in late infantile neuronal ceroid lipofuscinosis. AJNR Am. J. Neuroradiol. 19, 1373\u20131377 (1998).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"138_CR257","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3174\/ajnr.A3297","volume":"34","author":"JP Dyke","year":"2013","unstructured":"Dyke, J. P. et al. Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging. AJNR Am. J. Neuroradiol. 34, 884\u2013889 (2013).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"138_CR258","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3174\/ajnr.A0551","volume":"28","author":"JP Dyke","year":"2007","unstructured":"Dyke, J. P. et al. Assessing disease severity in late infantile neuronal ceroid lipofuscinosis using quantitative MR diffusion-weighted imaging. AJNR Am. J. Neuroradiol. 28, 1232\u20131236 (2007).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"138_CR259","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","volume":"69","author":"RE Williams","year":"2017","unstructured":"Williams, R. E. et al. Management strategies for CLN2 disease. Pediatr. Neurol. 69, 102\u2013112 (2017).","journal-title":"Pediatr. Neurol."},{"key":"138_CR260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0887-8994(92)90032-T","volume":"8","author":"T Autti","year":"1992","unstructured":"Autti, T., Raininko, R., Launes, J., Nuutila, A. & Santavuori, P. Jansky-Bielschowsky variant disease: CT, MRI, and SPECT findings. Pediatr. Neurol. 8, 121\u2013126 (1992).","journal-title":"Pediatr. Neurol."},{"key":"138_CR261","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00019052-199712000-00015","volume":"10","author":"T Autti","year":"1997","unstructured":"Autti, T., Raininko, R., Vanhanen, S. L. & Santavuori, P. Magnetic resonance techniques in neuronal ceroid lipofuscinoses and some other lysosomal diseases affecting the brain. Curr. Opin. Neurol. 10, 519\u2013524 (1997).","journal-title":"Curr. Opin. Neurol."},{"key":"138_CR262","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ana.410420517","volume":"42","author":"I Jarvela","year":"1997","unstructured":"Jarvela, I. et al. Clinical and magnetic resonance imaging findings in Batten disease: analysis of the major mutation (1.02-kb deletion). Ann. Neurol. 42, 799\u2013802 (1997).","journal-title":"Ann. Neurol."},{"key":"138_CR263","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1076\/1381-6810(200006)2121-8FT069","volume":"21","author":"LB Eksandh","year":"2000","unstructured":"Eksandh, L. B. et al. Full-field ERG in patients with Batten\/Spielmeyer-Vogt disease caused by mutations in the CLN3 gene. Ophthalmic Genet. 21, 69\u201377 (2000).","journal-title":"Ophthalmic Genet."},{"issue":"Suppl. A","key":"138_CR264","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/ejpn.2000.0454","volume":"5","author":"P Santavuori","year":"2001","unstructured":"Santavuori, P., Vanhanen, S. L. & Autti, T. Clinical and neuroradiological diagnostic aspects of neuronal ceroid lipofuscinoses disorders. Eur. J. Paediatr. Neurol. 5 (Suppl. A), 157\u2013161 (2001).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"138_CR265","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10545-011-9421-6","volume":"35","author":"J Cialone","year":"2012","unstructured":"Cialone, J. et al. Females experience a more severe disease course in Batten disease. J. Inherit. Metab. Dis. 35, 549\u2013555 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"138_CR266","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ajmg.1320310608","volume":"5","author":"RM Boustany","year":"1988","unstructured":"Boustany, R. M., Alroy, J. & Kolodny, E. H. Clinical classification of neuronal ceroid-lipofuscinosis subtypes. Am. J. Med. Genet. Suppl. 5, 47\u201358 (1988).","journal-title":"Am. J. Med. Genet. Suppl."},{"key":"138_CR267","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1046\/j.1528-1157.2003.39802.x","volume":"44","author":"JG Burneo","year":"2003","unstructured":"Burneo, J. G. et al. Adult-onset neuronal ceroid lipofuscinosis (Kufs disease) with autosomal dominant inheritance in Alabama. Epilepsia 44, 841\u2013846 (2003).","journal-title":"Epilepsia"},{"key":"138_CR268","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1212\/WNL.55.4.579","volume":"55","author":"V Holmberg","year":"2000","unstructured":"Holmberg, V. et al. Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5). Neurology 55, 579\u2013581 (2000).","journal-title":"Neurology"},{"key":"138_CR269","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1212\/WNL.0000000000001784","volume":"85","author":"L Canafoglia","year":"2015","unstructured":"Canafoglia, L. et al. Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations. Neurology 85, 316\u2013324 (2015).","journal-title":"Neurology"},{"key":"138_CR270","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/mgg3.263","volume":"5","author":"C Beesley","year":"2017","unstructured":"Beesley, C. et al. CLN8 disease caused by large genomic deletions. Mol. Genet. Genomic Med. 5, 85\u201391 (2017).","journal-title":"Mol. Genet. Genom. Med."},{"key":"138_CR271","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1399-0004.2011.01777.x","volume":"81","author":"NM Allen","year":"2012","unstructured":"Allen, N. M. et al. Variant late-infantile neuronal ceroid lipofuscinosis due to a novel heterozygous CLN8 mutation and de novo 8p23.3 deletion. Clin. Genet. 81, 602\u2013604 (2012).","journal-title":"Clin. Genet."},{"key":"138_CR272","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1399-0004.2009.01285.x","volume":"77","author":"K Reinhardt","year":"2010","unstructured":"Reinhardt, K. et al. Novel CLN8 mutations confirm the clinical and ethnic diversity of late infantile neuronal ceroid lipofuscinosis. Clin. Genet. 77, 79\u201385 (2010).","journal-title":"Clin. Genet."},{"key":"138_CR273","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00415-016-8111-6","volume":"263","author":"S Doccini","year":"2016","unstructured":"Doccini, S. et al. Early infantile neuronal ceroid lipofuscinosis (CLN10 disease) associated with a novel mutation in CTSD. J. Neurol. 263, 1029\u20131032 (2016).","journal-title":"J. Neurol."},{"key":"138_CR274","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-0037-1613681","volume":"49","author":"K Varvagiannis","year":"2018","unstructured":"Varvagiannis, K. et al. Congenital neuronal ceroid lipofuscinosis with a novel CTSD gene mutation: a rare cause of neonatal-onset neurodegenerative disorder. Neuropediatrics 49, 150\u2013153 (2018).","journal-title":"Neuropediatrics"},{"key":"138_CR275","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ajhg.2012.04.021","volume":"90","author":"KR Smith","year":"2012","unstructured":"Smith, K. R. et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 90, 1102\u20131107 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"138_CR276","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1212\/WNL.0000000000000953","volume":"83","author":"R Fabio Di","year":"2014","unstructured":"Di Fabio, R. et al. Pseudo-dominant inheritance of a novel CTSF mutation associated with type B Kufs disease. Neurology 83, 1769\u20131770 (2014).","journal-title":"Neurology"},{"key":"138_CR277","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/hmg\/dds558","volume":"22","author":"KR Smith","year":"2013","unstructured":"Smith, K. R. et al. Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum. Mol. Genet. 22, 1417\u20131423 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"138_CR278","doi-asserted-by":"crossref","first-page":"13566","DOI":"10.1073\/pnas.251485198","volume":"98","author":"P Gupta","year":"2001","unstructured":"Gupta, P. et al. Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. Proc. Natl Acad. Sci. USA 98, 13566\u201313571 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"138_CR279","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.stem.2009.05.022","volume":"5","author":"SJ Tamaki","year":"2009","unstructured":"Tamaki, S. J. et al. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell 5, 310\u2013319 (2009).","journal-title":"Cell Stem Cell"},{"key":"138_CR280","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ymthe.2005.04.018","volume":"12","author":"M Griffey","year":"2005","unstructured":"Griffey, M., Macauley, S. L., Ogilvie, J. M. & Sands, M. S. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol. Ther. 12, 413\u2013421 (2005).","journal-title":"Mol. Ther."},{"key":"138_CR281","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/hmg\/ddq555","volume":"20","author":"H Wei","year":"2011","unstructured":"Wei, H. et al. Disruption of adaptive energy metabolism and elevated ribosomal p-S6K1 levels contribute to INCL pathogenesis: partial rescue by resveratrol. Hum. Mol. Genet. 20, 1111\u20131121 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"138_CR282","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10545-011-9446-x","volume":"35","author":"MS Roberts","year":"2012","unstructured":"Roberts, M. S. et al. Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis. J. Inherit. Metab. Dis. 35, 847\u2013857 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"138_CR283","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.ymgme.2017.12.338","volume":"123","author":"AJ Rozenberg","year":"2018","unstructured":"Rozenberg, A. J., Lykken, E., Spratt, K., Miller, T. J. & Gray, S. J. Combination dosing of CLN1 gene therapy extends lifespan in a mouse model of infantile neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 123, S124 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR284","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.nbd.2004.02.010","volume":"16","author":"E Bible","year":"2004","unstructured":"Bible, E., Gupta, P., Hofmann, S. L. & Cooper, J. D. Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16, 346\u2013359 (2004).","journal-title":"Neurobiol. Dis."},{"key":"138_CR285","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.nbd.2006.09.001","volume":"25","author":"C Kielar","year":"2007","unstructured":"Kielar, C. et al. Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 25, 150\u2013162 (2007).","journal-title":"Neurobiol. Dis."},{"key":"138_CR286","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.expneurol.2009.01.022","volume":"217","author":"SL Macauley","year":"2009","unstructured":"Macauley, S. L. et al. Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse. Exp. Neurol. 217, 124\u2013135 (2009).","journal-title":"Exp. Neurol."},{"key":"138_CR287","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ymthe.2017.03.037","volume":"25","author":"Y Meng","year":"2017","unstructured":"Meng, Y. et al. A basic ApoE-based peptide mediator to deliver proteins across the blood-brain barrier: long-term efficacy, toxicity, and mechanism. Mol. Ther. 25, 1531\u20131543 (2017).","journal-title":"Mol. Ther."},{"key":"138_CR288","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/ddu428","volume":"24","author":"JN Miller","year":"2015","unstructured":"Miller, J. N., Kov\u00e1cs, A. D. & Pearce, D. A. The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy. Hum. Mol. Genet. 24, 185\u2013196 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"138_CR289","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/jcmm.12744","volume":"20","author":"V Thada","year":"2016","unstructured":"Thada, V., Miller, J. N., Kovacs, A. D. & Pearce, D. A. Tissue-specific variation in nonsense mutant transcript level and drug-induced read-through efficiency in the Cln1(R151X) mouse model of INCL. J. Cell. Mol. Med. 20, 381\u2013385 (2016).","journal-title":"J. Cell. Mol. Med."},{"key":"138_CR290","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/mt.2011.130","volume":"19","author":"S Xu","year":"2011","unstructured":"Xu, S. et al. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 19, 1842\u20131848 (2011).","journal-title":"Mol. Ther."},{"key":"138_CR291","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1523\/JNEUROSCI.2676-05.2006","volume":"26","author":"MA Passini","year":"2006","unstructured":"Passini, M. A. et al. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J. Neurosci. 26, 1334\u20131342 (2006).","journal-title":"J. Neurosci."},{"key":"138_CR292","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1042\/bj3570049","volume":"357","author":"L Lin","year":"2001","unstructured":"Lin, L. & Lobel, P. Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis. Biochem. J. 357, 49\u201355 (2001).","journal-title":"Biochem. J."},{"key":"138_CR293","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176526","volume":"12","author":"RD Geraets","year":"2017","unstructured":"Geraets, R. D. et al. A tailored mouse model of CLN2 disease: a nonsense mutant for testing personalized therapies. PLOS ONE 12, e0176526 (2017).","journal-title":"PLOS ONE"},{"key":"138_CR294","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1097-4547(19990815)57:4<551::AID-JNR15>3.0.CO;2-R","volume":"57","author":"ML Katz","year":"1999","unstructured":"Katz, M. L. et al. A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease). J. Neurosci. Res. 57, 551\u2013556 (1999).","journal-title":"J. Neurosci. Res."},{"key":"138_CR295","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.brainres.2004.07.030","volume":"1023","author":"CC Pontikis","year":"2004","unstructured":"Pontikis, C. C. et al. Late onset neurodegeneration in the Cln3\u2212\/\u2212 mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res. 1023, 231\u2013242 (2004).","journal-title":"Brain Res."},{"key":"138_CR296","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.nbd.2005.05.018","volume":"20","author":"CC Pontikis","year":"2005","unstructured":"Pontikis, C. C., Cotman, S. L., MacDonald, M. E. & Cooper, J. D. Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7\/8 knock-in mouse model of Batten disease. Neurobiol. Dis. 20, 823\u2013836 (2005).","journal-title":"Neurobiol. Dis."},{"key":"138_CR297","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.nbd.2007.08.017","volume":"29","author":"ML Katz","year":"2008","unstructured":"Katz, M. L., Johnson, G. S., Tullis, G. E. & Lei, B. Phenotypic characterization of a mouse model of juvenile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 29, 242\u2013253 (2008).","journal-title":"Neurobiol. Dis."},{"key":"138_CR298","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1601-183X.2009.00478.x","volume":"8","author":"NS Osorio","year":"2009","unstructured":"Osorio, N. S. et al. Neurodevelopmental delay in the Cln3Deltaex7\/8 mouse model for Batten disease. Genes Brain Behav. 8, 337\u2013345 (2009).","journal-title":"Genes Brain Behav."},{"key":"138_CR299","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainres.2009.02.009","volume":"1266","author":"JM Weimer","year":"2009","unstructured":"Weimer, J. M. et al. Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res. 1266, 93\u2013107 (2009).","journal-title":"Brain Res."},{"key":"138_CR300","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.nbd.2018.04.010","volume":"115","author":"ML Schultz","year":"2018","unstructured":"Schultz, M. L. et al. Modulating membrane fluidity corrects Batten disease phenotypes in vitro and in vivo. Neurobiol. Dis. 115, 182\u2013193 (2018).","journal-title":"Neurobiol. Dis."},{"key":"138_CR301","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1750-3639.2004.tb00502.x","volume":"14","author":"HM Mitchison","year":"2004","unstructured":"Mitchison, H. M., Lim, M. J. & Cooper, J. D. Selectivity and types of cell death in the neuronal ceroid lipofuscinoses. Brain Pathol. 14, 86\u201396 (2004).","journal-title":"Brain Pathol."},{"key":"138_CR302","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.nbd.2005.11.008","volume":"22","author":"JM Weimer","year":"2006","unstructured":"Weimer, J. M. et al. Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol. Dis. 22, 284\u2013293 (2006).","journal-title":"Neurobiol. Dis."},{"key":"138_CR303","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.brainres.2007.05.018","volume":"1162","author":"JM Weimer","year":"2007","unstructured":"Weimer, J. M. et al. Alterations in striatal dopamine catabolism precede loss of substantia nigra neurons in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res. 1162, 98\u2013112 (2007).","journal-title":"Brain Res."},{"key":"138_CR304","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1167\/iovs.03-0039","volume":"44","author":"RM Sappington","year":"2003","unstructured":"Sappington, R. M., Pearce, D. A. & Calkins, D. J. Optic nerve degeneration in a murine model of juvenile ceroid lipofuscinosis. Invest. Ophthalmol. Vis. Sci. 44, 3725\u20133731 (2003).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"138_CR305","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.neuropharm.2012.05.040","volume":"63","author":"AD Kovacs","year":"2012","unstructured":"Kovacs, A. D. et al. Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. Neuropharmacology 63, 769\u2013775 (2012).","journal-title":"Neuropharmacology"},{"key":"138_CR306","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-319-75402-4_12","volume":"1074","author":"SM Kleine Holthaus","year":"2018","unstructured":"Kleine Holthaus, S. M., Smith, A. J., Mole, S. E. & Ali, R. R. Gene therapy approaches to treat the neurodegeneration and visual failure in neuronal ceroid lipofuscinoses. Adv. Exp. Med. Biol. 1074, 91\u201399 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"138_CR307","first-page":"196","volume":"171","author":"FE Rosato","year":"1990","unstructured":"Rosato, F. E. et al. Selective arterial stimulation of secretin in localization of gastrinomas. Surg. Gynecol. Obstet. 171, 196\u2013200 (1990).","journal-title":"Surg. Gynecol. Obstet."},{"key":"138_CR308","volume":"8","author":"JP Morgan","year":"2013","unstructured":"Morgan, J. P. et al. A murine model of variant late infantile ceroid lipofuscinosis recapitulates behavioral and pathological phenotypes of human disease. PLOS ONE 8, e78694 (2013).","journal-title":"PLOS ONE"},{"key":"138_CR309","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ana.410330408","volume":"33","author":"RT Bronson","year":"1993","unstructured":"Bronson, R. T., Lake, B. D., Cook, S., Taylor, S. & Davisson, M. T. Motor neuron degeneration of mice is a model of neuronal ceroid lipofuscinosis (Batten\u2019s disease). Ann. Neurol. 33, 381\u2013385 (1993).","journal-title":"Ann. Neurol."},{"key":"138_CR310","first-page":"1071","volume":"35","author":"B Chang","year":"1994","unstructured":"Chang, B. et al. Retinal degeneration in motor neuron degeneration: a mouse model of ceroid lipofuscinosis. Invest. Ophthalmol. Vis. Sci. 35, 1071\u20131076 (1994).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"138_CR311","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1006\/mgme.1999.2817","volume":"66","author":"A Messer","year":"1999","unstructured":"Messer, A., Manley, K. & Plummer, J. A. An early-onset congenic strain of the motor neuron degeneration (mnd) mouse. Mol. Genet. Metab. 66, 393\u2013397 (1999).","journal-title":"Mol. Genet. Metab."},{"key":"138_CR312","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0006-8993(97)00612-4","volume":"785","author":"K Fujita","year":"1998","unstructured":"Fujita, K. et al. Increase of glial fibrillary acidic protein fragments in the spinal cord of motor neuron degeneration mutant mouse. Brain Res. 785, 31\u201340 (1998).","journal-title":"Brain Res."},{"key":"138_CR313","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2990.2011.01233.x","volume":"38","author":"M Kuronen","year":"2012","unstructured":"Kuronen, M. et al. Galactolipid deficiency in the early pathogenesis of neuronal ceroid lipofuscinosis model Cln8mnd: implications to delayed myelination and oligodendrocyte maturation. Neuropathol. Appl. Neurobiol. 38, 471\u2013486 (2012).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"138_CR314","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0006-8993(02)02470-8","volume":"937","author":"VJ Bolivar","year":"2002","unstructured":"Bolivar, V. J., Scott Ganus, J. & Messer, A. The development of behavioral abnormalities in the motor neuron degeneration (mnd) mouse. Brain Res. 937, 74\u201382 (2002).","journal-title":"Brain Res."},{"key":"138_CR315","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1046\/j.1460-9568.2002.02299.x","volume":"16","author":"M Bertamini","year":"2002","unstructured":"Bertamini, M. et al. Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system. Eur. J. Neurosci. 16, 2291\u20132296 (2002).","journal-title":"Eur. J. Neurosci."},{"key":"138_CR316","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/cmdc.200600144","volume":"1","author":"B Elger","year":"2006","unstructured":"Elger, B. et al. Optimized synthesis of AMPA receptor antagonist ZK 187638 and neurobehavioral activity in a mouse model of neuronal ceroid lipofuscinosis. ChemMedChem 1, 1142\u20131148 (2006).","journal-title":"ChemMedChem"},{"key":"138_CR317","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/(SICI)1097-4547(19971001)50:1<123::AID-JNR13>3.0.CO;2-C","volume":"50","author":"ML Katz","year":"1997","unstructured":"Katz, M. L., Rice, L. M. & Gao, C. L. Dietary carnitine supplements slow disease progression in a putative mouse model for hereditary ceroid-lipofuscinosis. J.\u00a0Neurosci. Res. 50, 123\u2013132 (1997).","journal-title":"J. Neurosci. Res."},{"key":"138_CR318","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.expneurol.2004.03.006","volume":"187","author":"RJ Zeman","year":"2004","unstructured":"Zeman, R. J., Peng, H. & Etlinger, J. D. Clenbuterol retards loss of motor function in motor neuron degeneration mice. Exp. Neurol. 187, 460\u2013467 (2004).","journal-title":"Exp. Neurol."},{"key":"138_CR319","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/NEN.0b013e318238fc28","volume":"70","author":"S Koch","year":"2011","unstructured":"Koch, S. et al. Morphologic and functional correlates of synaptic pathology in the cathepsin D knockout mouse model of congenital neuronal ceroid lipofuscinosis. J. Neuropathol. Exp. Neurol. 70, 1089\u20131096 (2011).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"138_CR320","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1523\/JNEUROSCI.20-18-06898.2000","volume":"20","author":"M Koike","year":"2000","unstructured":"Koike, M. et al. Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J. Neurosci. 20, 6898\u20136906 (2000).","journal-title":"J. Neurosci."},{"key":"138_CR321","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/nen.0b013e31815f3899","volume":"67","author":"S Partanen","year":"2008","unstructured":"Partanen, S. et al. Synaptic changes in the thalamocortical system of cathepsin D-deficient mice: a model of human congenital neuronal ceroid-lipofuscinosis. J. Neuropathol. Exp. Neurol. 67, 16\u201329 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"138_CR322","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2353\/ajpath.2010.091267","volume":"177","author":"Z Shevtsova","year":"2010","unstructured":"Shevtsova, Z. et al. CNS-expressed cathepsin D prevents lymphopenia in a murine model of congenital neuronal ceroid lipofuscinosis. Am. J. Pathol. 177, 271\u2013279 (2010).","journal-title":"Am. J. Pathol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0138-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0138-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0138-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T18:43:42Z","timestamp":1720982622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-019-0138-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":322,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["138"],"URL":"https:\/\/doi.org\/10.1038\/s41582-019-0138-8","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,19]]},"assertion":[{"value":"19 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}